Crimean-Congo Hemorrhagic Fever (CCHF) is a highly virulent viral
disease characterized by a rapid onset of symptoms and significant mortality rates. The
primary mode of transmission to humans is through tick bites, particularly from the
Hyalomma genus, or through direct contact with infected animals or humans.
Clinically, CCHF typically begins with the abrupt onset of fever, myalgia, headache,
nausea, vomiting, and diarrhea. As the disease advances, patients may exhibit severe
hemorrhagic manifestations, including extensive bruising, epistaxis, and uncontrolled
bleeding from venipuncture sites. The progression can result in multi-organ failure,
with a fatality rate of up to 40%. CCHF is endemic in regions of Africa, Asia, Eastern
Europe, and the Mediterranean. Recent decades have seen an expansion of its
geographic range, attributed to factors such as climate change and increased global
movement. Populations at elevated risk include healthcare workers and individuals
involved in livestock handling and meat processing. Currently, the management of
CCHF is primarily supportive, as there are no specific antiviral treatments approved for
this disease. Key preventive measures include avoiding tick bites, adhering to safe
practices during meat processing, and using personal protective equipment properly.
Continuous surveillance, ongoing research, and robust public health preparedness are
crucial to address this escalating global health threat effectively.
Keywords: CCHFV, Climate changes, Crimean-Congo Hemorrhagic Fever, Infection control, Nairovirus, Public health, Ribavirin, Tick-borne disease, Vaccine development, Viral hemorrhagic fever.
